Hepatitis B Virus (HBV) Prenatal Screen, HBsAg
Also known as: HBsAg, Hepatitis
Use
Screening of pregnant women for hepatitis B virus (HBV) infection to identify neonates who are at risk of acquiring hepatitis B during the perinatal period.
Special Instructions
This test may exhibit interference when the sample is collected from an individual consuming a supplement with high doses of biotin (vitamin B7/B8, vitamin H, coenzyme R). Patients should avoid biotin consumption at least 72 hours prior to sample collection.
Limitations
Patients negative for HBsAg could still have acute hepatitis B infection due to low antigen levels below assay detection limits or lack of antigen reactivity to the antibodies used in the assay. Negative results in previously exposed individuals may likewise be due to these factors. Testing in cases with strong clinical suspicion of viral hepatitis should not be limited to detecting HBsAg but should include a battery of tests like antibodies to hepatitis B core antigen (anti-HBc) and HBV DNA.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 5196-1
- 5196-1
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3.5 mL
Minimum Volume
1.5 mL
Container
Gel-barrier tube, red-top tube or serum transfer tube
Collection Instructions
If tube other than a gel-barrier tube is used, transfer separated serum to a screw-cap polypropylene transport tube. Do not freeze gel-barrier tube (pour off serum first).
Storage Instructions
Room temperature
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |